Drug Profile
Research programme: RNA-targeted therapeutics - Roche/Santaris Pharma
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Roche; Santaris Pharma
- Developer Roche
- Class Antisense RNA; Oligonucleotides
- Mechanism of Action Antisense RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Undefined in Denmark
- 28 Jul 2018 No recent reports of development identified for research development in Undefined in USA
- 09 Jan 2014 Early research in Undefined indication in Denmark (unspecified route)